Introduction
The dysmetabolic syndrome and diabetes are becoming more and more prevalent in the Western world and also in many developing countries. Clearly, treatment is quite important in the prevention of cardiovascular disease, as well as end-stage renal failure. Some patients are at high risk, particularly diabetic patients with microalbuminuria, 1, 2 and these patients are the main focus in this paper. Hypertension is a key issue, and blood pressure-lowering treatment is becoming increasingly important in these patients and also in the prevention of microalbuminuria. Key features of the therapeutic approach include blocking of the reninangiotensin system along with the use of diuretics. 2 It is well known that patients with diabetes quite often have sodium retention related to the blood pressure elevation, and therefore diuretic treatment is important, 2 bearing in mind that blood glucoselowering treatment sometimes has to be intensified as a result. There has been discussion on whether to start with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II type 1 receptor blockers (ARBs) or with diuretics. European experts in diabetes generally recommend blocking the renin-angiotensin system. 3 The American point of view may be early treatment with diuretics. 4 This apparent controversy is somewhat artificial, because most patients will clearly need combination therapy in order to achieve the goal of a blood pressure below 130/85 mmHg, 5 and even a high-normal blood pressure constitutes a considerable risk for cardiovascular disease. 6 The PREterax in albuMInuria rEgRession (PRE-MIER) (Figure 1 ) study emphasizes the role of combination therapies, since Preterax (the lowdose combination of indapamide and perindopril) is more effective than enalapril in hypertensive and diabetic patients with microalbuminuria. 7 This study was designed as a 12-month, randomized, controlled, double-blind, two-parallel group study conducted in 104 centres in 20 countries. In all, 457 patients were randomized into two groups, to the low-dose perindopril/indapamide combination or enalapril. The low-dose perindopril/indapamide combination resulted in a statistically significant higher fall in both blood pressure (for systolic blood pressure, À3.05; 95% confidence interval [CI], À5.6 to À0.4], P ¼ 0.0012; for diastolic blood pressure, À1.5; 95% CI, À3.0 to À0.1; P ¼ 0.0019) and albumin excretion rate (AER) (À42%; 95% CI, À50 to À33%, vs À27%; 95% CI, À37 to À16% with enalapril). The greater AER reduction remained significant after adjustment for mean blood pressure. Analysis of serious cardiovascular adverse events showed an incidence of 2.5% (six of 244) in the perindopril/ indapamide group vs 6.3% (15 of 227) in the enalapril group (relative risk ¼ 2.65; 95% CI, 1.03-6.83; log-rank test, P ¼ 0.036) (Figure 2 ). 7 There is also increasing focus on the dysmetabolic syndrome, and the prevalence of microalbuminuria clearly increases with the number of risk factors for the metabolic syndrome, as shown by Chen et al.
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Although microalbuminuria is not traditionally part of the metabolic syndrome, clearly microalbuminuria really strengthens the case for treatment, optimizing blood pressure therapy as well as glycaemic control. The challenge is, therefore, to screen for microalbuminuria, start treatment early and effectively, and possibly start treatment with agents (even with a 'normal' blood pressure) that block the reninangiotensin system, combined with diuretics. Arguments for such a more radical and early blood pressure-lowering strategy will be put forward in this paper.
Prevention of diabetes (and its complications) -ACE inhibitor and ARB?
In the treatment of hypertension in nondiabetic individuals, great care should be taken to select agents that do not confer an increased risk for the development of new diabetes. The aim should be to use agents that may at least be neutral for, or even to some extent protect against, the development of glucose intolerance. Hypertensive patients have a 1-2% annual risk of developing diabetes. [8] [9] [10] [11] [12] A number of studies have shown that both ACE inhibitors and ARBs seem to confer an antidiabetic effect, at least when compared with diuretics and b-blockers. The recently published Valsartan Antihypertensive Long-term Use Evaluation (VALUE) study 13 also showed that the ARB valsartan confers benefits in protecting against diabetes in comparison with the calcium channel blocker (CCB) amlodipine, with a highly significantly reduced risk of the development of new type II diabetes after 5 years. A summary of the clinical trial evidence to date is provided in Table 1 . 8 Thus, a strong argument can already be made for the initial selection of these agents rather than diuretics and b-blockers alone, and now, perhaps, even CCBs. This applies particularly to patients with cardiovascular disease and hypertension, and probably also to individuals with uncomplicated hypertension. 8 However, the issue is not completely resolved. First of all, we need a more definitive study, such as the ongoing Diabetes REduction Approaches with ramipril and rosiglitazone Medications (DREAM) study, which will assess the effects of ramipril and rosiglitazone in patients at high risk of developing diabetes. We also need more information on the mechanisms of action of antihypertensives, since details are not clearly understood.
Furthermore, while it is evident that both classes of drugs that inhibit the renin-angiotensin system appear to be beneficial, an important question remains: is one class superior for the prevention of the development of cardiovascular and renal disease? This particular issue has now been addressed to some extent by the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) trial.
14 DETAIL was a much-needed, long-term study comparing an ACE inhibitor with an ARB headto-head in a diabetic population. The 5-year, prospective, multicentre, double-blind study directly compared the ACE inhibitor enalapril with the ARB telmisartan in patients with type II diabetes, hypertension and evidence of early nephropathy, and in many cases microalbuminuria. DETAIL was also the first study of its kind to monitor the progression of kidney disease by directly measuring the glomerular filtration rate (GFR), now recognized as the best indicator of overall renal function and end-stage renal disease (ESRD).
The fall in GFR at 5 years -the main end pointwas the same in patients treated with either drug, with changes in GFR from baseline of around À17 ml/min/1.73 m 2 in the telmisartan group and À15 ml/min/1.73 m 2 in the enalapril group. Analysis of the secondary end point of the yearly change in GFR revealed an initial steep decline in GFR in both groups, of around À8 ml/min/1.73 m 2 , which then stabilized to around À2 ml/min/1.73 m 2 beyond 3 years.
Blood pressure was lowered to a comparable degree in each treatment group, and cardiovascular mortality was much lower than would be expected at 5 years, with three and five cardiovascular-related deaths in the telmisartan and enalapril groups, respectively. Other adverse event rates were similar between the two groups, since ACE inhibitorintolerant patients were excluded from the study, and there were no cases of ESRD in either group.
Other shorter studies have indicated that ACE inhibitors and ARBs exert similar effects as far as albuminuria and blood pressure are concerned. [15] [16] [17] Furthermore, dual blockade using a drug of each class is a possible approach in patients who do not respond to single blockade. 17 Thus, with the latest results from DETAIL in mind, the clinician may choose either an ACE inhibitor or an ARB, or even the two in combination. However, questions remain regarding the longer term in advanced nephropathy. The strong end point studies, namely the Reduction of End points in Noninsulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL) study and the Irbesartan type 2 Diabetic Nephropathy Trial (IDNT), in patients with type II diabetes and overt nephropathy, should be considered. 18, 19 The results of these studies appear to favour the use of ARBs, and as yet there are no similar studies comparing ACE inhibitors with ARBs to provide further information in this patient group.
Preventing microalbuminuria in diabetes
Patients with normoalbuminuria have also been examined, first in type II diabetes, with an ACE inhibitor by Ravid et al. 20 The ACE inhibitor prevented the development of microalbuminuria. Kvetny et al 21 showed the same in an important study on type I diabetes using perindopril. 21 The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT) was recently published. 22 Indeed, it is important to distinguish between normoalbuminuria and microalbuminuria and renal insufficiency as confirmed in the study by Adler et al 23 from the United Kingdom Prospective Diabetes Study (UKPDS). Clearly, patients with normoalbuminuria have the best prognosis, and there is strong evidence to show that preventing progression is associated with a much better prognosis, which was also documented in the recent paper by Gaede and co-workers from the Steno Diabetes Center. They showed that remission to normoalbuminuria is associated with much better preservation of renal function in terms of GFR fall, which is stabilized. 24, 25 Thus, the most recent and comprehensive study regarding primary prevention, meaning that microalbuminuria can be prevented in type II diabetes, comes from the BENEDICT study group in Bergamo. 22 This is the largest study so far conducted, and, very interestingly, this study also compares an ACE inhibitor with a calcium channel blocker, verapamil (a so-called nondihydropyridine). This was a large study in Northern Italy, comprising 1204 patients randomly assigned to 3 years of treatment with trandolapril alone, trandolapril þ verapamil, verapamil alone, and placebo. 22 Interestingly, hypertension was defined as low as a blood pressure X130/85 mmHg or as the need for antihypertensive treatment to attain a systolic or diastolic blood pressure under these levels. The primary end point was development of persistent microalbuminuria with an overnight AER higher than 20 mg/min on two consecutive occasions.
The primary outcome was seen in 6% of the patients treated with the ACE inhibitor alone and in 10% of the patients receiving placebo, and there was a clear significant difference (P ¼ 0.01). Treatment with verapamil alone was not different from placebo. The authors also estimated the so-called acceleration factors, which were clearly in favour of the use of the ACE inhibitor. There were only minor differences in blood pressure between the treatment arms, but this may still have played a role for the positive results with ACE inhibitors. There were few serious events in the two treatment groups. The conclusion was clear: in patients with type II diabetes and hypertension (above 130/85 mmHg), but with normoalbuminuria, treatment with an ACE inhibitor was clearly beneficial in preventing the development of microalbuminuria, the first sign of renal damage. Microalbuminuria is a major risk factor for vascular events, and obviously also for advanced renal disease and death. 23 In conclusion, there is now fairly good evidence from clinical trials that treatment with an ACE inhibitor should be started early in patients with type II diabetes and normoalbuminuria. Treatment should be initiated when systolic blood pressure is more than 130 mmHg systolic. Systolic blood pressure elevation is very common in patients with type II diabetes and the metabolic syndrome. 1 This means that most patients with type II diabetes mellitus would qualify for this type of treatment. These patients also often show sodium retention and therefore a combination with an ACE inhibitor and diuretics seem to be most effective in reducing microalbuminuria and blood pressure. 7 There now seems to be a very good foundation for substantial improvements in outcome for patients with type II diabetes. Thus, early treatment of hypertension leads to a better prognosis, as does improved euglycaemic control. 26 Clearly, treatment with statins is also important, as documented in many studies, among others in the Steno 2 study. 25 Now we have apparently completed the paradigm shift: it is essential to normalize glycaemia, blood pressure and dyslipidaemia in all patients with type II diabetes. Genetic factors (as is commonly believed in the United States) have not been documented to play any significant role, 27 but there is clearly much more room for intensified clinical care in patients with type II diabetes, as outlined in this and previous articles.
The effect of ACE inhibitors and ARBs on renal outcomes and mortality: studies in diabetic nephropathy
During an oral presentation in San Francisco of the important studies on ARBs and overt diabetic nephropathy (type II diabetes), 18, 19 one of the very interested doctors/physicians in the audience asked one of the principal investigators why they had not compared ACE inhibitors with ARBs, since we know that ACE inhibitors are quite effective in type I and type II diabetes according to many studies. The principal investigators became slightly annoyed and came up with a rude reply, but clearly this question was very relevant, and we now have an important article on this topic, which was recently published. 28 It is an excellent meta-analysis conducted in a very systematic way.
The question put forward in this paper was relevant and clear: when considering all studies on ACE inhibitors and ARBs on renal outcomes and allcause mortality in patients with diabetic nephropathy, is there a difference? The data sources were solid: Medline, EMBASE, and the Cochrane Central Register for controlled clinical trials and contacts with investigators.
The data extracted concerned mortality and renal outcomes, which were: (1) prevention of progression of micro-and macroalbuminuria as well as regression to normoalbuminuria; (2) doubling of the serum creatinine concentration; (3) ESRD, and the final outcome in all studies: mortality.
All the relevant papers were identified based on the date of submission, comprising about 7500 patients. Of major interest in this area is ESRD, and renal dysfunction. BENEDICT, BErgamo NEphrologic DIabetes Complications Trial; PREMIER, PREterax in albuMInuria rEgRession.
New concepts in blood pressure-lowering managementImportantly, both agents had a similar effect on both renal outcomes, including when confounders were taken into consideration. Comparing ACE inhibitors directly with ARBs was at that time difficult, but results from a new study (DETAIL) are now available. 14 The important point here is that ACE inhibitors had a significant effect on overall mortality, mainly driven by the Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation (MICRO-HOPE) study. The test for the overall effect on mortality had a P-value of 0.04. In contrast, the ARBs had no significant effect on mortality, with a P-value of 0.95. This is important, because patients with renal disease may not die from ESRD (they undergo dialysis): the cause of death, especially in type II diabetes, is primarily cardiac mortality. The same result is also seen in a large Chinese study. 29 Another impressive finding is that there was a very significant effect on regression from microalbuminuria to normoalbuminuria by ACE inhibitors, an effect that has been observed previously for type I diabetes. 30 The authors 28 finally point out the need for more comparative trials. In addition, the authors conclude that combination therapy -including the use of diuretics -is important. 7 Combining ACE inhibitors with ARBs also seems interesting especially in nondiabetic disease, as reported in the Combination of Angiotensin II Receptor Blocker and AngiotensinConverting Enzyme Inhibitor in Non-diabetic Renal Disease (COOPERATE) trial. 31 However, new studies are badly needed, also within this area, and work is in progress. 32 It is well known that ACE inhibitors have an effect on accumulation of bradykinin, 33 which may be beneficial and relevant to the main results of the meta-analysis. Thus, the pendulum may now be swinging in favour of ACE inhibition, but generally there is a positive effect of blocking the reninangiotensin system, as seen in Table 2 . The PREMIER study documented an excellent effect on blood pressure as well as cardiovascular end points (see Figures 1 and 2 ).
Conclusion
There is increasing focus on the treatment of even marginally elevated blood pressure in diabetic patients. For many years, the focus has been on patients with microalbuminuria and diabetes, but now there is even more emphasis on preventing microalbuminuria in diabetic patients, thus treating patients before any significant renal damage occurs. This is also likely to have a beneficial effect on all vascular end points. Studies from the UKPDS and other studies indicate that blood pressure should be as low as possible, probably by blocking the reninangiotensin system. The concomitant diuretic is of key importance, and it is proposed to start treatment with combination therapy in order to avoid postponement of effective treatment with the aim of normalizing blood pressure.
